These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 11678786)
21. Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy. Tarasi A; Cassone M; Monaco M; Tarasi D; Pompeo ME; Venditti M J Chemother; 2003 Jun; 15(3):239-43. PubMed ID: 12868549 [TBL] [Abstract][Full Text] [Related]
22. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus. Fitzgibbon MM; Rossney AS; O'Connell B J Clin Microbiol; 2007 Oct; 45(10):3263-9. PubMed ID: 17687008 [TBL] [Abstract][Full Text] [Related]
24. Glycopeptide and daptomycin susceptibility trends among clinical isolates of methicillin-resistant Staphylococcus aureus in a tertiary care center in North India. Singh A; Prasad KN; Rai RP; Singh SK; Rahman M; Tripathi A; Srivastava JK J Infect Public Health; 2015; 8(4):341-5. PubMed ID: 25797814 [TBL] [Abstract][Full Text] [Related]
25. [Staphylococcus infection in a multi-profile hospital in Nowy Targ, Poland, in the years 2001-2004 - analysis of antibiotic resistance]. Waksmahska W; Wiczkowski A; Bobihski R; Glemp-Migief A Med Dosw Mikrobiol; 2017; 69(1):5-13. PubMed ID: 30351620 [TBL] [Abstract][Full Text] [Related]
26. [Methicillin-resistant Staphylococcus aureus infection in a geriatric unit for acutely ill]. Selva O'Callaghan A; San José Laporte A; Almirante Gragera B; Vilardell Tarrés M Med Clin (Barc); 1998 May; 110(17):678. PubMed ID: 9656216 [No Abstract] [Full Text] [Related]
27. Incidence of glycopeptide hetero-intermediate Staphylococcus aureus strains in Maltese hospitals. Borg MA; Zerafa R; Morrison D; Cuschieri P Clin Microbiol Infect; 2005 May; 11(5):405-7. PubMed ID: 15819869 [TBL] [Abstract][Full Text] [Related]
28. [Determination of the in vitro activity of 2 glycopeptides (vancomycin and teicoplanin) against methicillin-resistant Staphylococcus aureus of intrahospital origin]. Gil M; Otth L; Wilson M; Arce E; Zaror A; Lizama V Rev Med Chil; 2000 Jan; 128(1):111-2. PubMed ID: 10883531 [No Abstract] [Full Text] [Related]
29. Staphylococcus aureus with reduced susceptibility to vancomycin in healthcare settings. Spagnolo AM; Orlando P; Panatto D; Amicizia D; Perdelli F; Cristina ML J Prev Med Hyg; 2014 Dec; 55(4):137-44. PubMed ID: 26137787 [TBL] [Abstract][Full Text] [Related]
30. [Activity of vancomycin and teicoplanin against clinical isolates of Staphylococcus aureus in the period 1994-1999]. Nashev D; Toshkova K; Gavrilova V Vutr Boles; 2000; 32(2):35-40. PubMed ID: 11227664 [TBL] [Abstract][Full Text] [Related]
31. The use and therapeutic drug monitoring of teicoplanin in the UK. Darley ES; MacGowan AP Clin Microbiol Infect; 2004 Jan; 10(1):62-9. PubMed ID: 14706088 [TBL] [Abstract][Full Text] [Related]
32. [The change and significance of vancomycin minimal inhibitory concentration against methicillin-resistant Staphylococcus aureus isolates from inpatients with lower respiratory tract infection]. Yang W; He B; Ning YZ; Li Y Zhonghua Jie He He Hu Xi Za Zhi; 2013 Apr; 36(4):288-92. PubMed ID: 23945344 [TBL] [Abstract][Full Text] [Related]
33. Vancomycin and teicoplanin use in Victorian hospitals. The Victorian Drug Usage Evaluation Group. Robertson MB; Dartnell JG; Korman TM Med J Aust; 1999 Aug; 171(3):127-31. PubMed ID: 10474603 [TBL] [Abstract][Full Text] [Related]
34. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. Sancak B; Ercis S; Menemenlioglu D; Colakoglu S; Hasçelik G J Antimicrob Chemother; 2005 Sep; 56(3):519-23. PubMed ID: 16046461 [TBL] [Abstract][Full Text] [Related]
35. Does surgical prophylaxis with teicoplanin constitute a therapeutic advance? Mini E; Nobili S; Periti P J Chemother; 2000 Nov; 12 Suppl 5():40-55. PubMed ID: 11131963 [TBL] [Abstract][Full Text] [Related]
36. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center. Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725 [TBL] [Abstract][Full Text] [Related]
38. Teicoplanin versus vancomycin for proven or suspected infection. Cavalcanti AB; Goncalves AR; Almeida CS; Bugano DD; Silva E Cochrane Database Syst Rev; 2010 Jun; (6):CD007022. PubMed ID: 20556772 [TBL] [Abstract][Full Text] [Related]
39. Multilocus sequence typing (MLST) shows that the 'Iberian' clone of methicillin-resistant Staphylococcus aureus has spread to France and acquired reduced susceptibility to teicoplanin. Heym B; Le Moal M; Armand-Lefevre L; Nicolas-Chanoine MH J Antimicrob Chemother; 2002 Sep; 50(3):323-9. PubMed ID: 12205056 [TBL] [Abstract][Full Text] [Related]
40. Vancomycin MIC creep in methicillin-resistant Staphylococcus aureus (MRSA) isolates from 2006 to 2010 in a hospital in China. Chang W; Ma X; Gao P; Lv X; Lu H; Chen F Indian J Med Microbiol; 2015; 33(2):262-6. PubMed ID: 25865979 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]